Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
Cabazitaxel Superior to Switching Antiandrogens for Third-Line mCRPC Treatment - Renal and Urology News
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Lu-177 Vipivotide Tetraxetan Yields Similar OS Versus Cabazitaxel in mCRPC Progressing After Docetaxel
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan | BMC Cancer | Full Text
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer | Future Oncology
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial - The Lancet
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer - Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier ...
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Choosing Chemotherapy for Castration-Resistant Prostate Cancer
ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer | SpringerLink
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
Cancers | Free Full-Text | Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA. JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010
New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Journal of Clinical Oncology on X: "Cabazitaxel vs docetaxel as 1st line tx for metastatic castration-resistant prostate cancer (FIRSTANA trial) https://t.co/0DliBtSjsc #pcsm https://t.co/ZEHKYfmO8L" / X
